Skip to content

Nordic Nanovector announces the appointment of Joanna Horobin, MD, as Non-executive Board Director

Oslo, Norway, 12 October 2016

Nordic Nanovector ASA (OSE: NANO) announces that Joanna Horobin was elected to its Board as Non-executive Director at the company’s Extraordinary General Meeting (EGM) held today in Oslo, Norway. Dr Horobin replaces Dr Renee P Tannenbaum who stepped down from the Board of Directors today for personal reasons.

Ms Horobin has comprehensive experience within the biopharmaceutical industry. She is currently Senior Vice President, Chief Medical Officer and a Member of the Leadership Team at Idera Pharmaceuticals, Inc. in Cambridge, MA, USA. Ms Horobin’s current role includes the development and regulatory strategy as well as the execution of the clinical trial programme for the company’s pipeline of novel oligonucleotides for the treatment of rare oncology and other indications.

Prior to this position, she was CMO of Verastem, Inc. and CEO of Syndax Pharmaceuticals. Additionally, Ms Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rhône Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer. Ms Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim) and played significant leadership roles in the approvals of several successful products.

For further information, please contact:

IR enquiries:

Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76

Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949

About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.

Further information about the Company can be found at

This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Source: Nordic Nanovector